A novel pathogenic variant in LCAT causing FLD. A case report

References

• Von Eckardstein A. Angeborene Störungen des High-density-Lipoprotein-Stoffwechsels. Internist (Berl) Internet]. 2019;60(12):1311–1318. Available from.;():.
   Google Scholar
• Pavanello C, Calabresi L. Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020. Curr Opin Lipidol. 2020;31(4):232–237.
   Google Scholar
• National Center for Advancing Translational Sciences (NIH). Genetic and Rare Diseases Information Centre (GARD). [Accessed21 October 2021]. : https://rarediseases.info.nih.gov/diseases/6450/fish-eye-disease
   Google Scholar
• Saeedi R, Li M, Frohlich J. A review on lecithin: cholesterol acyltransferase deficiency. Clin Biochem. 2015;48(7–8):472–475.
   Google Scholar
• Calabresi L, Simonelli S, Gomaraschi M, et al. Genetic lecithin: cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis Internet]. 2012;222(2):299–306. DOI: 10.1016/j.atherosclerosis.2011.11.034.
   Google Scholar
• Kanai M, Koh S, Masuda D, et al. Clinical features and visual function in a patient with Fish-eye disease: quantitative measurements and optical coherence tomography. Am J Ophthalmol Case Reports Internet]. 2018;10(February):137–141. DOI: 10.1016/j.ajoc.2018.02.016.
   Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405–424.
   Google Scholar
• Pikuleva IA, Curcio CA. Cholesterol in the retina: the best is yet to come. Prog Retin Eye Res. 2014;41:64–89.
   Google Scholar
• Pavanello C, Ossoli A, Arca M, et al. Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort. J Lipid Res Internet]. 2020;61(12):1784–1788. DOI:10.1194/jlr.P120000976.
   Google Scholar
• Gunawardane RN, Fordstrom P, Piper DE, et al. Agonistic human antibodies binding to lecithin-cholesterol acyltransferase modulate high density lipoprotein metabolism. J Biol Chem. 2016;291(6):2799–2811.
   Google Scholar
• Morales E, Alonso M, Sarmiento B, et al. LCAT deficiency as a cause of proteinuria and corneal opacification. BMJ Case Rep. 2018;2018:2017–2018.
   Google Scholar
• Lynn EG, Siow YL, Frohlich J, et al. Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-κB. Kidney Int. 2001;60(2):520–532.
   Google Scholar
• Lamiquiz-Moneo C, Gómez-Coronado B-V, Villafuerte-Ledesma G, et al. Lipid profile rather than the LCAT mutation explains renal disease in familial LCAT deficiency. J Clin Med. 2019;8(11):1860.
   Google Scholar
• Delteil C, Macagno N, and Appay R, et al. Glomérulopathie associée à un déficit en lécithine-cholestérol-acyltransférase: rapport de cas et revue de la littérature. Glomerulopathy associated with lecithin-cholesterol-acyltransferase deficiency: a case report and literature review. Marseille, France.: Aix Marseil 2018 .
   Google Scholar
• Najafian B, Lusco MA, Finn LS, et al. AJKD atlas of renal pathology: lecithin–cholesterol acyltransferase (LCAT) deficiency. Am J Kidney Dis Internet]. 2017;70(1):e5–6. DOI: 10.1053/j.ajkd.2017.05.003
   Google Scholar
• Suda Takeo, Akamatsu Akira, Nakaya, Yutaka, Masuda, Yasunobu, and Desaki, Junzo, et al. Alterations in erythrocyte membrane lipid and its fragility in a patient with familial lecithin:cholesterol acyltrasferase(LCAT) deficiency The journal of Medical Investigation 2002 . 49:147–155.
   Google Scholar
• Manthei KA, Ahn J, Glukhova A, et al. A retractable lid in lecithin: cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-I. J Biol Chem. 2017;292(49):20313–20327.
   Google Scholar
• Sensi C, Simonelli S, Zanotti I, et al. Distant homology modeling of LCAT and its validation through in silico targeting and in vitro and in vivo assays. PLoS One. 2014;9(4):e95044.
   Google Scholar
• Oldoni F, Baldassarre D, Castelnuovo S, et al. Complete and partial lecithin: cholesterolacyltransferase deficiency is differentially associated with atherosclerosis. Circulation. 2018;138(10):1000–1007.
   Google Scholar
• Schaefer EJ, Anthanont P, Diffenderfer MR, et al. Diagnosis and treatment of high density lipoprotein deficiency. Prog Cardiovasc Dis. 2016;59(2):97–106.
   Google Scholar
• Faguer S, Colombat M, et al. Administration of the high-density lipoprotein mimetic CER-001 for inherited lecithin–cholesterol acyltransferase deficiency. Ann Intern Med. 2021 Jul;174(7):1022–1025.
   Google Scholar
• Pavanello C, Ossoli A, Turri M. Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound. J Pharmacol Exp Ther. 2020 Dec;375(3):463–468.
   Google Scholar
• Baragetti A, Ossoli A, Strazzella A, et al. Low plasma lecithin: cholesterol acyltransferase (LCAT) concentration predicts chronic kidney disease. J Clin Med. 2020;9(7):2289.
   Google Scholar